Search for: "Ortho-McNeil, Inc."
Results 121 - 140
of 209
Sorted by Relevance
|
Sort by Date
28 Oct 2006, 8:56 am
Ortho-McNeil Pharm., Inc., 2006 U.S. [read post]
19 May 2010, 6:15 am
Immutopics, Inc. [read post]
13 Apr 2011, 5:13 pm
Ortho-McNeil-Janssen Pharmaceuticals, Inc., No. 2-10-cv-00836 (E.D. [read post]
28 Feb 2014, 9:27 pm
The companies that share responsibility for the development, manufacture, and promotion of these drugs include (1) Ortho-McNeil-Janssen Pharmaceuticals, Inc. [read post]
23 Jun 2009, 9:46 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Eloxatin (Oxaliplatin) – US: District Court New Jersey grants summary judgment of non-infringement in favour of Hospira, Teva and others concerning patent relating to Sanofi’s Eloxatin: Sanofi-Aventis v Sandoz (SmartBrief) (The IP Factor) (GenericsWeb) (Patents4Life) General Europe’s ever changing landscape Pirate Party,… [read post]
14 Jul 2010, 6:47 pm
Glaxo tries a ‘Linux’ (Spicy IP) TB Alliance and DNDi team up to fight neglected diseases (IP Watch) Australia: Pharmaceuticals extensions and international inequities: H Lundbeck A/S v Alphapharm Pty Ltd, Ortho-McNeil Pharmaceutical, Inc v Lupin Pharmaceuticals, Inc (Patentology) Australia: The ‘morality’ of gene patents (Patentology) Belgium: Antwerp commercial court finds Belgian counterpart of EU patent covering process for producing… [read post]
12 Nov 2009, 9:17 am
Ortho-McNeil Pharmaceutical, Inc., 463 F. [read post]
23 Apr 2010, 8:20 am
” Expected to attend are IP leaders from BP America Inc., Merck & Co., Inc., Bose, Brigham Young University, Cornell University, Stanford University, Duke University, Georgetown University, GlaxoSmithKline, Honeywell, Harvard University, Johnson & Johnson, Kauffman Foundation, Lockheed Martin, Massachusetts Institute of Technology (MIT), Mayo Clinic, Ortho-McNeil Pharmaceuticals Inc., Rutgers, Syngenta Biotechnology, Scripps Research… [read post]
10 Mar 2010, 5:22 am
Ortho-McNeil-Janssen Pharmaceuticals, Inc. [read post]
3 May 2010, 5:08 pm
” Ortho-McNeil Pharm., Inc. v. [read post]
10 Mar 2010, 5:22 am
Ortho-McNeil-Janssen Pharmaceuticals, Inc. [read post]
25 Aug 2011, 8:14 am
Ortho-McNeil, 520 F.3d at 1364-65 (“[A] flexible TSM test remains the primary guarantor against a non-statutory hindsight analysis . . . . [read post]
25 Aug 2011, 8:14 am
Bayer Schering, 575 F.3d at 1347 (citing O’Farrell, 853 F.2d at 903); see also Ortho-McNeil, 520 F.3d at 1364 (stating the number of options must be “small or easily traversed”). [read post]
18 Jan 2016, 5:00 am
Ortho-McNeil-Janssen Pharmaceuticals, Inc., 808 F.3d 281 (6th Cir. 2015) – preemption, but not involving generic drugs − which aptly described pre-approval theories as “never-start selling” claims (id. at 300), describes that other decision. [read post]
17 Jul 2017, 9:41 am
Par Pharm., Inc. v. [read post]
10 Jun 2009, 10:00 pm
Ortho-McNeil Pharmaceutical, 2007 WL 121149, at *4 (S.D. [read post]
7 Feb 2011, 6:53 pm
In Ortho-McNeil Pharmaceutical, Inc. v. [read post]
22 Jul 2009, 6:05 am
(PatLit) Levaquin (Levofloxacin) – US: CAFC awards only partial costs where depositions used in multiple cases from different district courts: Ortho-McNeil Pharmaceutical, Inc. v. [read post]
1 Jul 2009, 1:06 am
Levaquin, made by J&J subsidiary Ortho-McNeil Pharmaceutical Inc., was approved by the Food and Drug Administration in 1996, but in July 2008, the FDA warned that Levaquin, and other drugs in the fluoroquinolone class of antibiotics, put users at heightened risk of developing tendonitis and tendon ruptures. [read post]
3 Jun 2012, 12:17 pm
" Ortho-McNeil Pharm. [read post]
